KALA
KALA BIO, Inc.
$2.63
+6.48%
$48.9M
No data for this timeframe.
Vol
Market Cap$48.9M
Cap SizeNano Cap
Reddit Sentiment50° Neutral
SEC Reports1
Press Releases1
Recent Activity
May 13, 2026
earnings_calendar
KALA Q1 2026 Earnings Before Market Open — 2026-05-13
May 7, 2026
SEC
KALA BIO filed an S-3 shelf registration to issue an unlimited amount of senior and subordinated debt securities. The fi
S-3 — Impact 2/10
Mar 4, 2026
Press
KALA BIO announced a strategic initiative to become a dedicated AI infrastructure provider for the biotech industry by d
Impact 6/10
Analyst Ratings
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 29, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Sep 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Sep 11, 2025 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Sep 8, 2025 | Mizuho | INITIATE | Outperform |
| May 23, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Latest Reports
Reddit Sentiment
50°▲
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 2.0/10.
Historical analyst distribution (last covering-analyst action Sep 2025): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 29, 2025 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Sep 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 11, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Sep 8, 2025 | Mizuho | INITIATE | — | Outperform |
| May 23, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 4, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 19, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| May 17, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 2, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 1, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| Nov 17, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 11, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 10, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| May 1, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Apr 12, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Mar 27, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Mar 6, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Jan 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
6 mentions
2 bullish
2 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 7, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 22, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 15, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Apr 15, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
KALA stock
▲ 1
💬 1
⚡ 0.5
May 13, 2026
earnings_calendar
KALA Q1 2026 Earnings Before Market Open — 2026-05-13
May 12, 2026
earnings_calendar
KALA Q1 2026 Earnings Before Market Open — 2026-05-12
May 8, 2026
short_volume
Short Volume: KALA — 57.2% short (2.3M / 4.0M)
Short: 2,266,580 | Exempt: 309,606 | TRF Vol: 3,963,220 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
short_volume
Short Volume: KALA — 62.0% short (2.1M / 3.4M)
Short: 2,084,627 | Exempt: 527,755 | TRF Vol: 3,364,687 | Short Ratio: 62.0% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: KALA — 60.8% short (2.8M / 4.5M)
Short: 2,758,086 | Exempt: 500,440 | TRF Vol: 4,536,597 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
earnings_calendar
KALA Q4 2025 Earnings After Market Close — 2026-04-06
Apr 1, 2026
other
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Engagement will assess KALA’s clinical assets, development options, and AI-enabled analytical opportunities, including the MSC Secretome platform <pre
Apr 1, 2026
short_volume
Short Volume: KALA — 62.4% short (1.7M / 2.8M)
Short: 1,726,032 | Exempt: 12,687 | TRF Vol: 2,766,736 | Short Ratio: 62.4% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
other
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Next-Generation Agentic AI Platform Achieves Live Enterprise Deployment, Delivering Secure, Scalable, Autonomous Research Solutions to Global Biotechn
Mar 30, 2026
earnings_calendar
KALA Q4 2025 Earnings After Market Close — 2026-03-30
Mar 23, 2026
short_volume
Short Volume: KALA — 56.7% short (1.1M / 2.0M)
Short: 1,120,962 | Exempt: 96,780 | TRF Vol: 1,975,348 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Mar 11, 2026
other
Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates
Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks <pre>Platform Rebrand of Researgency.ai
Mar 4, 2026
contract
KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”
<p align="justify">ARLINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“<strong>KALA</strong>” or the “<strong>Compa